Novo Nordisk's (NVO) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a ...
Novo Nordisk, the pharmaceutical company behind Ozempic, has launched a national campaign promoting its injectable ...
Researchers highlighted on Monday that certain genes may help identify patients with obesity who are most likely to respond strongly to Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy ...
FAT jabs could be the cancer hope of the future after early studies found they reduce the risk of tumours. The world’s top ...
Novo Nordisk is facing the prospect of intensifying competition in the promising Chinese market where drugmakers are ...
Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.
A NEW weight loss drug could hijack the brain like a ‘Trojan horse’ to double weight loss. The drug could help the body to ...
Not only has the Danish economy benefited from the success of Ozempic and Wegovy, two more weight-management medications ...
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.
Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE 06/06 RE Novo Nordisk fait face à la concurrence en Chine pour l'ingrédient clé de ...
Les actions européennes progressent grâce aux valeurs technologiques à l'approche de la décision de la BCE 06/06 RE Novo Nordisk fait face à la concurrence en Chine pour l'ingrédient clé de ...